FAST NEWS: Hutchmed Sells Cancer Drug’s Overseas Rights for up to $1.13 Billion
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced on Wednesday that it has exclusively licensed Japan’s Takeda Pharmaceutical (TAK.US; 4502.T) to develop, manufacture and sell its metastatic colorectal cancer drug…
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
FAST NEWS: Hutchmed swings to profit on strong revenue growth
HCM.US 0013.HK
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter